Background
The non-invasive assessment of the haemodynamic significance of coronary artery disease is still challenging. Cardiac MR perfusion imaging during the first pass after i.v. administration of an extracellular contrast agents is limited by the spatial and temporal resolution achievable as well as by the artifacts seen in ultrafast MR-imaging. Moreover the patient must be stressed while being inside the magnet. Two injections of contrast are required, and a time consuming data analysis is necessary.
The use of molecular MR-imaging by means of a target specific contrast agent with perfusion dependent binding to myocardium may enable prolonged visualization of perfusion defects and thus may help to overcome limitations of currently used first pass extracellular MRI. EP-3600, a peptide-gadolinium hybrid, is a new Gd-containing molecular contrast agent which binds reversibly to myocardial collagen. It consists of a 15 amino acid peptide that is functionalized with three Gd-DOTA type chelates on the N-terminus. In contrast to the compound EP-3533 recently reported [1, 2] , EP-3600 uses the DOTA chelator.
The aim of this study was to investigate the potential of EP-3600 for the assessment of myocardial perfusion defects in a swine model of coronary artery stenosis.
Methods
A significant coronary artery stenosis was modeled in 8 domestic swine using an undersized MR-compatible balloon positioned in the LAD as verified by X-ray angiography. Two animals died prior to contrast injection due to arrythmias. In 5 swine, high spatial resolution T1-weighted gradient echo imaging was performed prior, 5, 20, 40 and 60 minutes after i.v. administration of 12.3 μmol/kg EP-3600. Imaging parameter included a saturation-preparation prepulse (103 ms for each slice), cardiac triggering, TR = 4.6 ms, TE = 1.4 ms, flip angle = 12°, fieldof-view of 270 × 270 mm2, matrix of 256 × 256 with an in-plane reconstructed voxel size of 1.05 × 1.05 mm2, SENSE-factor 2.1, total imaging time for five 10 mm thick slices 21 seconds at a heart rate of 80 beats/minutes allowing for breath-hold imaging. Contrast was administered during stress induced by an infusion of 250 μmol/kg/min adenosine. One further swine served as a control and received 0.05 mmol of standard Gd-DTPA. Yb-DTPA was administered simultaneously in 5 pigs for comparison of myocardium/plasma ratios. Images were subjectively assessed by two investigators (good contrast, and signal-to-noise (SNR) and contrastto-noise ratio (CNR) over time were calculated.
Results
Normal myocardium showed a significant SNR increase during the entire examination time. In all animals which received EP-3600 (n = 5), the perfusion defect in the LAD territory could be visualized with a high CNR for at least 20 minutes post contrast injection (Figure 1) . A significant higher myocardium/plasma ratio was found for EP3600 compared to the control agent Yb-DTPA (0.88 ± 0.26 vs 0.22 ± 0.08 respectively, p < 0.01). In the control swine which received standard Gd-DTPA no perfusion defect was visible at 5 minutes post injection or at later time points.
Conclusion
EP-3600 is a new molecular MR-imaging contrast agent which binds to the myocardium and enables prolonged, high contrast and high spatial resolution visualization of myocardial perfusion defects.
